NO20084998L - Tolags tablett for a avverge kardiovaskulaere folger - Google Patents

Tolags tablett for a avverge kardiovaskulaere folger

Info

Publication number
NO20084998L
NO20084998L NO20084998A NO20084998A NO20084998L NO 20084998 L NO20084998 L NO 20084998L NO 20084998 A NO20084998 A NO 20084998A NO 20084998 A NO20084998 A NO 20084998A NO 20084998 L NO20084998 L NO 20084998L
Authority
NO
Norway
Prior art keywords
layer tablet
pharmaceutically acceptable
ward
compound
cardiovascular consequences
Prior art date
Application number
NO20084998A
Other languages
English (en)
Inventor
Marta Guerrero
Antonio Guglietta
Anna Orriols
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38556680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084998(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of NO20084998L publication Critical patent/NO20084998L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår en to-lags tablett som innbefatter en del som inneholder en farmasøytisk akseptabel simvastatinforbindelse som dens aktive ingrediens; og samtidig en separat del som inneholder en farmasøytisk akseptabel lisinoprilforbindelse og en farmasøytisk akseptabel folsyreforbindelse som aktive ingredienser, for hindring av slag ved høy-risiko tilstander eller sykdommer.
NO20084998A 2006-05-24 2008-11-28 Tolags tablett for a avverge kardiovaskulaere folger NO20084998L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200601355A ES2300188B1 (es) 2006-05-24 2006-05-24 Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
PCT/EP2007/004631 WO2007134870A1 (en) 2006-05-24 2007-05-24 Bilayer tablet for preventing cardiovascular events

Publications (1)

Publication Number Publication Date
NO20084998L true NO20084998L (no) 2009-02-23

Family

ID=38556680

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084998A NO20084998L (no) 2006-05-24 2008-11-28 Tolags tablett for a avverge kardiovaskulaere folger

Country Status (24)

Country Link
US (1) US20090196922A1 (no)
EP (1) EP2026769B1 (no)
JP (1) JP2009537583A (no)
KR (1) KR20090020577A (no)
CN (1) CN101453992A (no)
AR (1) AR061047A1 (no)
AT (1) ATE460924T1 (no)
AU (1) AU2007253580B2 (no)
BR (1) BRPI0712267A2 (no)
CA (1) CA2652838A1 (no)
CY (1) CY1110097T1 (no)
DE (1) DE602007005372D1 (no)
DK (1) DK2026769T3 (no)
ES (2) ES2300188B1 (no)
HK (1) HK1129577A1 (no)
MX (1) MX2008014782A (no)
NO (1) NO20084998L (no)
PL (1) PL2026769T3 (no)
PT (1) PT2026769E (no)
RU (1) RU2445088C2 (no)
SI (1) SI2026769T1 (no)
TW (1) TW200812647A (no)
UY (1) UY30365A1 (no)
WO (1) WO2007134870A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ584521A (en) * 2007-10-10 2011-03-31 Avantor Performance Mat Inc Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
LT2498758T (lt) * 2009-11-13 2018-11-26 Astrazeneca Ab Dvisluoksnės tabletės formuluotės
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
PL2838516T3 (pl) 2012-04-18 2019-05-31 SpecGx LLC Zapobiegające nadużywaniu kompozycje farmaceutyczne o natychmiastowym uwalnianiu
WO2014059512A1 (en) * 2012-10-15 2014-04-24 Isa Odidi Oral drug delivery formulations
WO2014152296A1 (en) 2013-03-15 2014-09-25 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
WO2016004170A1 (en) 2014-07-03 2016-01-07 Mallinckrodt Llc Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US20160375087A1 (en) * 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
RU2018105849A (ru) * 2015-07-17 2019-08-19 Эббви Инк. Твердые фармацевтические композиции для лечения вируса гепатита с
AU2018258170B2 (en) 2017-04-25 2023-06-29 Otsuka Pharmaceutical Co., Ltd. Lisinopril compositions with an ingestible event marker
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
DK1272220T4 (en) * 2000-04-10 2016-11-28 Nicholas John Wald Cardiovascular disease prevention formulation
US6462174B1 (en) * 2001-06-25 2002-10-08 Astrazeneca Ab Amorphous compound
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
CN100383202C (zh) * 2002-02-05 2008-04-23 株式会社理光 喷墨记录用油墨、油墨组、油墨盒、记录装置、记录方法
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
BRPI0412557A (pt) * 2003-07-28 2006-09-19 Reddys Lab Inc Dr forma de dosagem farmacêutica de eventos cardiovasculares
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets

Also Published As

Publication number Publication date
BRPI0712267A2 (pt) 2012-01-17
MX2008014782A (es) 2008-11-28
RU2008151105A (ru) 2010-06-27
TW200812647A (en) 2008-03-16
EP2026769A1 (en) 2009-02-25
ES2300188A1 (es) 2008-06-01
CN101453992A (zh) 2009-06-10
ES2342905T3 (es) 2010-07-16
SI2026769T1 (sl) 2010-08-31
AU2007253580A1 (en) 2007-11-29
HK1129577A1 (en) 2009-12-04
AU2007253580B2 (en) 2012-03-22
PL2026769T3 (pl) 2010-09-30
US20090196922A1 (en) 2009-08-06
UY30365A1 (es) 2007-08-31
ES2300188B1 (es) 2009-05-01
CY1110097T1 (el) 2015-01-14
PT2026769E (pt) 2010-06-11
KR20090020577A (ko) 2009-02-26
RU2445088C2 (ru) 2012-03-20
CA2652838A1 (en) 2007-11-29
ATE460924T1 (de) 2010-04-15
DK2026769T3 (da) 2010-07-19
EP2026769B1 (en) 2010-03-17
DE602007005372D1 (de) 2010-04-29
JP2009537583A (ja) 2009-10-29
AR061047A1 (es) 2008-07-30
WO2007134870A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
NO20084998L (no) Tolags tablett for a avverge kardiovaskulaere folger
UA102673C2 (ru) Применение йота-каррагенана как противовирусного активного ингредиента
MY148496A (en) Dpp iv inhibitor formulations
WO2009118359A3 (en) Capsule for the prevention of cardiovascular diseases
WO2010066749A3 (en) Ulipristal acetate tablets
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
EA201170960A1 (ru) Твердая фармацевтическая композиция, содержащая амлодипин и лозартан
TN2016000230A1 (en) Orally disintegrating solid dosage unit containing an estetrol component.
JP2009537554A5 (no)
NO20085302L (no) Farmasoytisk preparat omfattende Amlodipin og Losartan
WO2009081174A3 (en) Anti - retroviral combination
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
WO2010031832A3 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010049449A3 (en) Novel salts of sunitinib
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2011011420A3 (en) 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
WO2009015446A3 (en) Triazole derivatives as viral replication inhibitors
WO2008009802A3 (fr) Medicaments comprenant un inhibiteur des alpha-mannosidases de classe i pour le traitement des sarcoglycanopathies
WO2010075086A3 (en) Pyrrolidinone inhibitors of pde-4
ATE508737T1 (de) Clopidogrel-hydrogensulfat von polymorph 1 form enthaltende pharmazeutische zusammensetzung
WO2008147169A8 (es) Microemolsion conteniendo pirfenidona
CY1114028T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια των ακροχορδωνων
AR089710A1 (es) Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c
WO2011052884A3 (ko) 테오브로민 함유 서방성 정제